[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2007003546A - Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa. - Google Patents

Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa.

Info

Publication number
MX2007003546A
MX2007003546A MX2007003546A MX2007003546A MX2007003546A MX 2007003546 A MX2007003546 A MX 2007003546A MX 2007003546 A MX2007003546 A MX 2007003546A MX 2007003546 A MX2007003546 A MX 2007003546A MX 2007003546 A MX2007003546 A MX 2007003546A
Authority
MX
Mexico
Prior art keywords
indozolone
derivatives
hsd1 inhibitors
formula
hsd1
Prior art date
Application number
MX2007003546A
Other languages
English (en)
Inventor
Werner Neidhart
Bernd Kuhn
Daniel Hunziker
Jianping Cai
Alexander Mayweg
Robert Alan Goodnow Jr
Kurt Amrein
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2007003546A publication Critical patent/MX2007003546A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen los compuestos de la formula (I) (Ver Formula) asi como las sales y esteres farmaceuticamente aceptables de los mismos, en la que R1 a R7 tienen los significados definidos en la descripcion y en las reivindicaciones, los cuales se pueden utilizar en forma de composiciones farmaceuticas. Los compuestos de la formula (I) son inhibidores 11b-HSD1.
MX2007003546A 2004-09-29 2005-09-21 Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa. MX2007003546A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04104753 2004-09-29
PCT/EP2005/010175 WO2006034804A1 (en) 2004-09-29 2005-09-21 Indozolone derivatives as 11b-hsd1 inhibitors

Publications (1)

Publication Number Publication Date
MX2007003546A true MX2007003546A (es) 2007-05-18

Family

ID=35447579

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007003546A MX2007003546A (es) 2004-09-29 2005-09-21 Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa.

Country Status (28)

Country Link
US (1) US7528158B2 (es)
EP (1) EP1797042B1 (es)
JP (1) JP4682207B2 (es)
KR (1) KR100856164B1 (es)
CN (1) CN101027286B (es)
AR (1) AR050952A1 (es)
AT (1) ATE420076T1 (es)
AU (1) AU2005289107B2 (es)
BR (1) BRPI0515931A (es)
CA (1) CA2581865C (es)
DE (1) DE602005012292D1 (es)
DK (1) DK1797042T3 (es)
ES (1) ES2317305T3 (es)
HK (1) HK1107348A1 (es)
HR (1) HRP20090151T3 (es)
IL (1) IL182212A (es)
MX (1) MX2007003546A (es)
MY (1) MY140841A (es)
NO (1) NO20071617L (es)
NZ (1) NZ553849A (es)
PL (1) PL1797042T3 (es)
PT (1) PT1797042E (es)
RU (1) RU2392272C2 (es)
SG (1) SG148178A1 (es)
SI (1) SI1797042T1 (es)
TW (1) TWI309646B (es)
WO (1) WO2006034804A1 (es)
ZA (1) ZA200702394B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
EP2046753A2 (en) * 2006-07-06 2009-04-15 Brystol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20090076783A1 (en) * 2007-09-13 2009-03-19 Tyco Healthcare Retail Services Ag Digitally optimized fastener assembly and method of making the same
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US8299048B2 (en) * 2008-03-06 2012-10-30 Merck Sharp & Dohme Corp. Hexahydrocyclopentyl[f]indazole sulfonamides and derivatives thereof as selective glucocorticoid receptor modulators
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
KR101796781B1 (ko) 2016-05-20 2017-11-13 한국화학연구원 신규한 인다졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84944A (en) 1987-01-19 1992-02-16 Ici Plc Pharmaceutical compositions containing 1,2-dihydro-3h-indazolone derivatives,some new such compounds and their preparation
GB9805520D0 (en) 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
SE0001899D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
FR2836914B1 (fr) * 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
CA2485681C (en) 2002-05-24 2012-10-16 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
KR20060101772A (ko) * 2003-12-19 2006-09-26 화이자 인코포레이티드 당뇨병 및 비만을 치료하기 위한,11-베타-하이드록시스테로이드 데하이드로게나제 유형1(11-베타-hsd-1)의 저해제로서의벤젠설폰일아미노-피리딘-2-일 유도체 및 관련 화합물

Also Published As

Publication number Publication date
TW200626558A (en) 2006-08-01
AR050952A1 (es) 2006-12-06
TWI309646B (en) 2009-05-11
RU2392272C2 (ru) 2010-06-20
AU2005289107A1 (en) 2006-04-06
US7528158B2 (en) 2009-05-05
RU2007116033A (ru) 2008-11-10
SI1797042T1 (sl) 2009-04-30
BRPI0515931A (pt) 2008-08-12
CN101027286B (zh) 2011-05-25
SG148178A1 (en) 2008-12-31
CA2581865C (en) 2010-04-20
EP1797042A1 (en) 2007-06-20
PT1797042E (pt) 2009-02-12
CA2581865A1 (en) 2006-04-06
PL1797042T3 (pl) 2009-06-30
IL182212A0 (en) 2007-07-24
US20060069269A1 (en) 2006-03-30
DK1797042T3 (da) 2009-03-02
HRP20090151T3 (en) 2009-04-30
CN101027286A (zh) 2007-08-29
IL182212A (en) 2011-03-31
WO2006034804A1 (en) 2006-04-06
AU2005289107B2 (en) 2010-12-16
NO20071617L (no) 2007-04-20
HK1107348A1 (en) 2008-04-03
ZA200702394B (en) 2008-11-26
ES2317305T3 (es) 2009-04-16
JP2008514659A (ja) 2008-05-08
ATE420076T1 (de) 2009-01-15
KR20070047839A (ko) 2007-05-07
JP4682207B2 (ja) 2011-05-11
NZ553849A (en) 2010-04-30
EP1797042B1 (en) 2009-01-07
MY140841A (en) 2010-01-29
DE602005012292D1 (de) 2009-02-26
KR100856164B1 (ko) 2008-09-03

Similar Documents

Publication Publication Date Title
MX2007003546A (es) Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa.
TW200608972A (en) Aryl-pyridine derivatives
HK1134087A1 (en) Pyridazine derivatives as 11beta-hydroxysteroid dehydrogenase type 1 inhibitors
MX2009003939A (es) Derivados de imidazolona e imidazolidinona como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 para diabetes.
IN2012DN03337A (es)
MX2009004441A (es) Derivados de indazol utiles como inhibidores de las isoformas de higado.
MX2010005824A (es) Derivados de aminotiazol.
TW200740764A (en) Pyrazolone derivatives
TW200526658A (en) Heterocyclic inhibitors of MEK and methods of use thereof
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
TW200716628A (en) Novel compounds
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
TW200745032A (en) Novel heterobicyclic derivatives
TW200722421A (en) Azole derivatives as inhibitors of lipases and phospholipases
MX2008016426A (es) Derivados de alquilpiridazina como inhibidores de 11 beta hidroxiesteroide deshidrogenasa tipo 1(11b-hsd 1).
TW200730513A (en) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
MX2010002584A (es) Derivados de piperidina como agonistas de receptores muscarinicos.
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
UA99787C2 (en) Lactams as beta secretase inhibitors
GB0314967D0 (en) Piperazine derivatives
IN2012DN01232A (es)
MX2009003169A (es) Derivados de sulfonamida.
MX2007003913A (es) Alquil-piridinas como inhibidores de 11 beta para diabetes.
MX2009013003A (es) Derivados de piperidina-amida.
MX2009007416A (es) Derivados de sulfonamida como inhibidores de quimasa.

Legal Events

Date Code Title Description
FG Grant or registration
HH Correction or change in general